SD-101; an intratumoral toll-like receptor 9 (TLR9) agonist, is a novel immune priming strategy that was shown to modify the TME by increasing local production of type 1 Interferon, resulting in cytotoxic T-cell infiltration and an anti-tumor response111. The gene discussed is TLR9; the disease is neoplasm.